WSK-V102 / WestVac Biopharma - LARVOL DELTA

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: WestVac Biopharma Co., Ltd. | N=600 ➔ 0 | Active, not recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102) (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jul 2024 ➔ Mar 2024

Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (clinicaltrials.gov) - P2 | N=450 | Completed | Sponsor: WestVac Biopharma Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster (clinicaltrials.gov) - P2 | N=600 | Active, not recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Nov 2023 ➔ Nov 2024

Enrollment closed • Trial completion date • Trial primary completion date • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) (clinicaltrials.gov) - P3 | N=4800 | Recruiting | Sponsor: WestVac Biopharma Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) (WSK-V102D). (clinicaltrials.gov) - P3 | N=4800 | Not yet recruiting | Sponsor: WestVac Biopharma Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases